| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.26583 |
| P8608 | Fatcat ID | release_noyqhkwqubdrnavivvf5dvgqhe |
| P932 | PMC publication ID | 6377365 |
| P698 | PubMed publication ID | 23787765 |
| P5875 | ResearchGate publication ID | 240309177 |
| P50 | author | Beth Holder | Q56433912 |
| P2093 | author name string | Giorgina Mieli-Vergani | |
| Yun Ma | |||
| Simon C Robson | |||
| John Cardone | |||
| Diego Vergani | |||
| Maria Serena Longhi | |||
| Rodrigo Liberal | |||
| Charlotte R Grant | |||
| P2860 | cites work | Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. | Q47219414 |
| Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. | Q51244795 | ||
| Autoimmune hepatitis in childhood: a 20-year experience. | Q53361457 | ||
| Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis | Q83316443 | ||
| IL-17 contributes to autoimmune hepatitis | Q84749635 | ||
| How regulatory T cells work | Q29614262 | ||
| Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression | Q29615344 | ||
| CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells | Q29618394 | ||
| Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression | Q33883569 | ||
| Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis | Q34090541 | ||
| CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice | Q34091467 | ||
| Expression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection. | Q34226860 | ||
| T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine | Q34578972 | ||
| Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. | Q34621389 | ||
| T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus | Q35199844 | ||
| Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells | Q36228688 | ||
| CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease | Q36566752 | ||
| From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease | Q37377260 | ||
| Aetiopathogenesis of autoimmune hepatitis | Q37600271 | ||
| Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. | Q41985015 | ||
| CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis | Q43241046 | ||
| A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis | Q44739483 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1007-1015 | |
| P577 | publication date | 2014-01-30 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis | |
| P478 | volume | 59 |
| Q41660660 | "Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis |
| Q35694206 | A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. |
| Q26753195 | Adaptive immunity in the liver |
| Q38358000 | Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations |
| Q39035161 | Adoptive cell transfer in autoimmune hepatitis |
| Q91654961 | Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCRβ-chain, which highlights the immunopathological aspect of the disease |
| Q35906055 | Autoimmune Hepatitis: Clinical Review with Insights into the Purinergic Mechanism of Disease |
| Q59349440 | Autoimmune hepatitis |
| Q86886381 | Autoimmune hepatitis |
| Q42365127 | Autoimmune hepatitis: 50 Years of (slow) progress |
| Q38692080 | Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. |
| Q38494826 | Autoimmune hepatitis: an approach to disease understanding and management |
| Q34550808 | Autoimmune hepatitis: current challenges and future prospects |
| Q42289803 | Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. |
| Q35202450 | CD39 deficiency in murine liver allografts promotes inflammatory injury and immune-mediated rejection |
| Q52868007 | CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease. |
| Q51050332 | CD39+ regulatory T cells attenuate allergic airway inflammation. |
| Q38285331 | Cell mediators of autoimmune hepatitis and their therapeutic implications |
| Q35088318 | Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease |
| Q36977772 | Current and potential immune therapies and vaccines in the management of psoriasis |
| Q48264506 | Distinct roles of ecto-nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in liver regeneration and fibrosis. |
| Q64274419 | Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity |
| Q55475388 | Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction. |
| Q64075135 | Ectonucleotidases in Intestinal and Hepatic Inflammation |
| Q34201736 | Efficacy and safety of immunosuppressive therapy in the treatment of seronegative hepatitis associated aplastic anemia |
| Q102152125 | Endogenous antisense RNA curbs CD39 expression in Crohn's disease |
| Q38730872 | Evolving paradigm of treatment for autoimmune hepatitis |
| Q90005422 | Fas, FasL and Foxp3 gene expression in post-liver transplant autoimmune hepatitis patients with and without acute rejection |
| Q34624054 | Gut microbiome and the risk factors in central nervous system autoimmunity. |
| Q56967377 | HIF-1α-induced xenobiotic transporters promote Th17 responses in Crohn's disease |
| Q38238921 | Hepatitis mouse models: from acute-to-chronic autoimmune hepatitis |
| Q42108248 | Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis |
| Q58799838 | Immune Alterations in Patients With Type 1 Autoimmune Hepatitis Persist Upon Standard Immunosuppressive Treatment |
| Q42369863 | Immunity and Fibrogenesis: The Role of Th17/IL-17 Axis in HBV and HCV-induced Chronic Hepatitis and Progression to Cirrhosis. |
| Q38930837 | Immunosuppressive drugs affect interferon (IFN)-γ and programmed cell death 1 (PD-1) kinetics in patients with newly diagnosed autoimmune hepatitis. |
| Q52945081 | In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression. |
| Q91950939 | Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future |
| Q52561169 | Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis. |
| Q47790004 | Involvement of the Nrf2/HO-1/CO axis and therapeutic intervention with the CO-releasing molecule CORM-A1, in a murine model of autoimmune hepatitis. |
| Q52564630 | NOD-Like Receptor Protein 3 Inflammasome-Dependent IL-1β Accelerated ConA-Induced Hepatitis. |
| Q90734771 | Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis |
| Q37607111 | Novel Immunotherapies for Autoimmune Hepatitis. |
| Q33898237 | Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy |
| Q58130515 | Phenotypic alterations of regulatory T cells in autoimmune hepatitis: causal or associated with treatment and remission? |
| Q38230723 | Purinergic signaling in liver disease. |
| Q37706119 | Rapamycin regulates iTreg function through CD39 and Runx1 pathways |
| Q35725777 | Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis |
| Q26827787 | Regulatory T cells: Mechanisms of suppression and impairment in autoimmune liver disease |
| Q52766142 | Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis. |
| Q87416598 | Reply: To PMID 23787765 |
| Q27025680 | Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets |
| Q38799687 | Surface Antigen Profiling of Helicobacter pylori-Infected and -Uninfected Gastric Cancer Cells Using Antibody Microarray. |
| Q39228029 | Th17 Responses to Collagen Type V, kα1-Tubulin, and Vimentin Are Present Early in Human Development and Persist Throughout Life |
| Q64968998 | The Imbalance between Foxp3+Tregs and Th1/Th17/Th22 Cells in Patients with Newly Diagnosed Autoimmune Hepatitis. |
| Q56378345 | The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator? |
| Q35849575 | The Role of Regulatory CD4 T Cells in Maintaining Tolerance in a Mouse Model of Autoimmune Hepatitis |
| Q39161005 | The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets |
| Q49036478 | The induction of autoimmune hepatitis in the human leucocyte antigen-DR4 non-obese diabetic mice autoimmune hepatitis mouse model. |
| Q38926183 | The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease |
| Q28069199 | The role of adenosinergic pathway in human autoimmune diseases |
| Q38543052 | Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases |
Search more.